FDA Grants Accelerated Approval to Inovio's Voceryq, First DNA Medicine for Recurrent Respiratory Papillomatosis

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Voceryq (INO-3107), Inovio Pharmaceuticals' DNA medicine designed for adults with recurrent respiratory papillomatosis (RRP). This approval marks the first U.S. FDA-approved DNA medicine. Voceryq aims to reduce the need for repeated surgeries in patients suffering from RRP, an HPV-driven disease characterized by wart-like growths in the throat and airways. A key study showed that 27% of patients who previously required frequent surgeries needed no surgical intervention in the 12 months following treatment. Inovio is required to conduct further studies to confirm the clinical benefit.